Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulatin...
LGC offers a comprehensive portfolio of reference standards and scientific tools for a wide range of disciplines. The focus of this talk will be on reference materials for clinical NGS produ...
Liquid biopsy next-generation sequencing (NGS) assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable or during disease progression. Extensiv...
Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinica...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, according to the World Health Organization. Many cancers can be cu...
Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Despite vast investment for decades in cancer research and development, cancer is still among the leading causes of death worldwide and its toll is expected to rise by about 70% over the next...
Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy. A liquid biopsy provides biomarker information that...
DATE: January 19th, 2017TIME: 8:00AM PT, 11:00AM ETLiquid biopsies have the potential to be a less invasive method than traditional biopsies to detect advanced solid tumor mutational st...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulatin...
LGC offers a comprehensive portfolio of reference standards and scientific tools for a wide range of disciplines. The focus of this talk will be on reference materials for clinical NGS produ...
Liquid biopsy next-generation sequencing (NGS) assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable or during disease progression. Extensiv...
Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinica...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, according to the World Health Organization. Many cancers can be cu...
Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
In this study, we evaluated the concordance of targeted sequencing results between paired ctDNA and tumor samples from early breast cancers scheduled for curative surgery with or without adj...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Genomic profiling of liquid biopsies is no longer an emerging area of clinical research, but quickly becoming translated as part of contemporary clinical trials for potential future use in t...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Despite vast investment for decades in cancer research and development, cancer is still among the leading causes of death worldwide and its toll is expected to rise by about 70% over the next...
Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy. A liquid biopsy provides biomarker information that...
DATE: January 19th, 2017TIME: 8:00AM PT, 11:00AM ETLiquid biopsies have the potential to be a less invasive method than traditional biopsies to detect advanced solid tumor mutational st...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...